Can a Person Have an Autoimmune Disorder and Polycythemia Vera Concurrently?
Yes, a patient can absolutely have both an autoimmune disease and polycythemia vera (PV) simultaneously, though this requires careful diagnostic evaluation to distinguish true coexistence from secondary causes of polycythemia.
Key Diagnostic Considerations
The WHO diagnostic criteria for PV explicitly address this scenario. When diagnosing primary myelofibrosis (which shares diagnostic principles with PV), the criteria specifically state that diagnosis requires "no evidence that bone marrow fibrosis is secondary to infection, autoimmune disorder or other chronic inflammatory condition" 1. However, this is critically nuanced: the guidelines also explicitly note that "patients with conditions associated with reactive myelofibrosis are not immune to primary myelofibrosis, and the diagnosis should be considered in such cases if other criteria are met" 1.
This same principle applies to PV—the presence of an autoimmune condition does not exclude PV if diagnostic criteria are otherwise fulfilled.
Documented Clinical Associations
Multiple lines of evidence confirm this coexistence:
Autoimmune conditions are well-documented with MPNs: Case reports demonstrate PV coexisting with rheumatoid arthritis, thrombotic thrombocytopenic purpura 2, and antiphospholipid syndrome 3
Thymoma associations: PV has been reported with thymoma, which itself is strongly associated with autoimmune diseases, possibly mediated through T-lymphocyte dysfunction 4
Connective tissue diseases: The WHO criteria for essential thrombocythemia (a related MPN) specifically list "connective tissue disease" among causes of reactive thrombocytosis, while noting that "the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of ET if other criteria are met" 1
Diagnostic Algorithm
When evaluating a patient with suspected PV who has an autoimmune disorder:
Confirm PV diagnosis using standard criteria 5:
- Hemoglobin ≥18.5 g/dL (men) or ≥16.5 g/dL (women)
- JAK2 V617F mutation or JAK2 exon 12 mutation
- Bone marrow biopsy showing panmyelosis
- Subnormal serum erythropoietin level
Rule out secondary polycythemia that could be driven by the autoimmune condition itself (e.g., chronic inflammation causing reactive changes)
Assess for treatment-induced complications: If the patient is on interferon therapy for PV, monitor for interferon-induced autoimmunity, which can cause Type 1 diabetes, autoimmune thyroiditis, systemic lupus erythematosus, or Sjögren's syndrome 6
Critical Management Pitfalls
Interferon therapy warning: Peginterferon-α, a first-line treatment for PV 7, can precipitate or worsen autoimmune conditions. This typically occurs within the first months but may be delayed. Type 1 diabetes induced by interferon is usually irreversible, while thyroiditis and lupus more often improve after withdrawal 6. Consider pre-treatment screening for anti-GAD antibodies and thyroid function in patients with personal or family history of autoimmune disease.
Thrombosis risk is compounded: Both PV and certain autoimmune conditions (particularly antiphospholipid syndrome) independently increase thrombotic risk 3. These patients require aggressive anticoagulation and cytoreductive therapy as indicated by standard PV risk stratification (age >60 or prior thrombosis) 7.
Treatment Approach
For patients with both conditions:
Maintain standard PV management: Phlebotomy to keep hematocrit <45%, low-dose aspirin (unless contraindicated by bleeding risk) 7
Consider hydroxyurea over interferon as first-line cytoreductive therapy if the patient has active autoimmune disease or high autoimmune risk, given interferon's propensity to trigger autoimmunity 6
Coordinate with rheumatology/immunology for management of the autoimmune condition, as immunosuppressive therapies may interact with MPN management
Monitor for disease progression: Both conditions require ongoing surveillance, and the presence of one should not distract from monitoring the other
The bottom line: True coexistence of autoimmune disorders and PV is possible and documented. The key is ensuring that PV diagnostic criteria are met independently, rather than attributing polycythemia solely to secondary causes related to the autoimmune condition.